Medical network - December 9 this year the pharmaceutical industry the highest level of regulation is likely to be announced in the middle of this month.
At an industry conference, many authoritative experts who are close to the policy making are confirmed, anecdotal high attention of "several opinions of further reform and improve the use for producing and distributing medicines" draft (hereinafter referred to as "draft") has passed the review of relevant departments, begin to enter the final review process, if no accident, is expected in the middle of this month.
To be sure, many big changes will begin in a few days later effects from drug research and development to production, circulation, the wholesale and end use of the whole supply chain, and each individual chain.
As early as in the earlier this year, the reform of medical field has been identified as the focus of the party central committee under the state council, in accordance with people close to the policy, reform of the state council office led to do drug distribution reform policy documents, at the same time let the state food and drug supervision on supply chain form file, to form a big reform file.
In July, after the basic written documents, the meeting decided to separate a few department under the state council to formulate the department files into a document, that is to be announced "further reform and improve the pharmaceutical production circulation use correct opinion" - because of the wide range, coordinate party involved is more, the organization reform office finally decided by the state council shall formulate work.
At present the latest progress is that file already by the central health reform leading group for review, agreed in principle to for advice, as soon as possible in mid-december.
The blue parker instrument has learned that, in view of the file enacted, officials have entrusted China health economic society develops the related demonstration research of the topic, in early November argument has passed the expert group recognition and cultivation.
But the industry thinks, the file after the drug sales are a great good, but may also need to enter the legislation level, namely, to the relevant provisions of the drugs act, modified and current revision comes as the third edition of the drug law.
And more immediate change is very likely will be the first to produce in the circulation field. Circulation still exist in the affiliated business, trading, fabricated data, the existence of these behaviors not only disturb the order of circulation, and the safety of the medicine circulation channels, undermine the fiscal and taxation policy, serious is that the quality of YaoXie bring unpredictable risks.
Under the above background, the sanming originated in the "two votes" in more recent file has the original "prices" main goals have been changed to "standardize the distribution order", "compress circulation" and so on.
The blue parker in the previous exclusive report on this issue was pointed out that the new rules or will definitely is engaged in the medicine representative sales work does not necessarily need the GSP certificate, the drug agents personal will really get great liberation, to full-time academic promotion and marketing work, don't have to go to the affiliated business company, to commercial companies go tickets and pay the fee, call don't have to worry about the fear of being caught, and have been checked.
This means more at the same time, thousands of YaoXie dealers, agents will find a new way, not because the policy of "two votes", etc.
Policy changes, it would have to redefine medicine distribution, wholesale, distribution, according to the current laws and regulations, to do medical business, need the GSP, warehouses, cost is very high.
Chinese medicine materials association deputy secretary-general WeiShaoFeng said China clearly does not need 13500 YaoXie warehouse, even if each county, 3000 is enough. As a result, many manufacturers are stepped on the edge of the law and YaoXie circulation of illegal cases in common, such as cie, make out an invoice, but these do not necessarily "unreasonable". Policy, will greatly benefit from wholesale, agents, small and medium-sized companies and individuals. |
